84 results about "Optic neuropathy" patented technology

Methods for analyzing retinal tomography maps to detect patterns of optic nerve diseases such as glaucoma, optic neuritis, anterior ischemic optic neuropathy are disclosed in this invention. The areas of mapping include the macula centered on the fovea, and the region centered on the optic nerve head. The retinal layers that are analyzed include the nerve fiber, ganglion cell, inner plexiform and inner nuclear layers and their combinations. The overall retinal thickness can also be analyzed. Pattern analysis are applied to the maps to create single parameter for diagnosis and progression analysis of glaucoma and optic neuropathy.

The present invention provides a method for lowering intraocular pressure and providing neuroprotection to a patient in need thereof by administering a therapeutically effective amount of at least one non-nucleotide or non-protein agent that inhibits expression and/or signaling of lysyl oxidase (LOX) or a lysyl oxidase-like protease (LOXL).

A reagent kit for the gene diagnosis of Leber's hereditary optical nerve (LHON) lesion which is caused by the mutations on 3 primary pathogenic sites (G11778A, G3460A and T14484C) is disclosed. Its detecting process includes such steps as designing and synthesizing the site specific PCR primer, using whole blood as DNA template, PCR amplification, and detecting said mutant sites of LHON patient.

Agents that stimulate nuclear translocation of Nrf2 protein and the subsequent increases in gene products that detoxify and eliminate cytotoxic metabolites are provided in a method for treating glaucomatous retinopathy or optic neuropathy. The structurally diverse agents that act on the Nrf2/ARE pathway induce the expression of enzymes and proteins that possess chemically versatile cytoprotective properties and are a defense against toxic metabolites and xenobiotics. Agents include certain electrophiles and oxidants such as a Michael Addition acceptor, diphenol, thiocarbamate, quinone, 1,2-dithiole-3-thione, butylated hydroxyanisole, flavonoid, an isothiocyanate, 3,5-di-tert-butyl-4-hydroxytoluene, ethoxyquin, a coumarin, combinations thereof, or a pharmacologically active derivative or analog thereof.

A system for analyzing and detecting early stage damage to the retina related to glaucoma. The reflectance of different wavelengths of light by the retinal nerve fiber layer are compared. Changes in relative reflectance values indicate damage to the retinal nerve fibers and indicate early glaucomatous optical neuropathy.

The present invention provides a method for lowering intraocular pressure and providing neuroprotection to a patient in need thereof by administering a therapeutically effective amount of at least one non-nucleotide or non-protein agent that inhibits expression and/or signaling of connective tissue growth factor (CTGF).

The present invention provides a peripheral ocular circulation ameliorant which contains dihydropyridines represented by the general formula (I) or their medicinally acceptable salts as active ingredients(where R1 is a nitrophenyl group and R2, R3, and R4 are lower alkyl groups), and particularly provides an optic disc blood flow ameliorant, choroidal blood flow ameliorant, retinal blood flow ameliorant, and accordingly, therapeutics for visual field defects associated with normal intraocular pressure glaucoma as well as for optic neuropathy, retinopathy, retinal-degeneration diseases, etc.

Antagonists of S1P3 (Edg-3) receptors are provided for attenuation of Smad signaling in a method of down-regulation of receptor signaling and downstream decreased production of connective tissue growth factor in ocular disorders involving CTGF accumulation. Ocular disorders involving inappropriate CTGF accumulation include ocular hypertension, glaucoma, glaucomatous retinopathy, optic neuropathy, macular degeneration, diabetic retinopathy, choroidal neovascularization, proliferative vitreoretinopathy and ocular wound healing, for example. Such disorders are treated by administering antagonists of the present invention.

The invention relates to a gene chip, and discloses an integrated detection gene chip of an mtDNA mutation site related to Leber genetic optic neuropathy, as well as the preparation and the application thereof. A specific oligonucleotide detecting probe of the mtDNA mutational site related to the Leber genetic optic neuropathy and a specific oligonucleotide detecting probe of a mononucleotide polymorphyism site mtDNA 11719G>A are fixed on the carrier surface lattice of the gene chip. The gene chip has the advantages of time saving, low cost, simple operation and the like, has 32 mutation sites related to the Leber genetic optic neuropathy in a specific detecting clinical sample only through one-time PCR amplification and one-time crossing reaction, and is suitable for the gene diagnosis of the Leber genetic optic neuropathy.

Based on optical coherence tomography (OCT) imaging of a portion of an eye, a mask of an anatomical feature is derived. Using the mask as a reference, a scan path is determined that is at least partially fitted to and/or partially enclosing the mask. OCT scan data corresponding to the scan path is acquired and analyzed to detect optic neuropathies.

The invention comprises methods and stem cell compositions for the treatment of diabetic retinopathy and other degenerative diseases of the eye. The invention is practiced in two stages with the first stage comprising the administration of neural stem cells to the eye, and the second stage comprising the administration of mesenchymal cells intravenously.

A use method of agmatine or a pharmaceutically allowable salt thereof, and a pharmaceutical composition comprising the same are disclosed. The method and pharmaceutical composition of the present invention can effectively cure or prevent eye diseases preferably including glaucoma, retinopathy, and optic neuropathy associated with apoptosis in retinal ganglion cells (RGCs), particularly hypoxia-induced or tumor necrosis factor-α (TNF-α)-induced apoptosis.

The invention discloses a medicament for improving eyesight. In the medicament, szechuan tangshen root, astragalus, large-headed atractylodes, Chinese angelica, rehmanniae vaporata, red paneoy root, rehmanniae praeparatum, gardenia fruit, medlar, eucommia bark, south dodder seed, raspberry, root of red-rooted salvia, notoginseng root, pale butterflybush flower, blackend swallowwort root, fish poison yarn and chrysanthemum are ground into 200-mesh powder, and are mixed uniformly, sterilized and packaged, wherein each bag contains 5 grams of medicament. The medicament is mainly used for treating patients who suffer from blurred vision caused by symptoms such as deficiency in kidney and yang, deficiency in blood and qi, diabetes mellitus, retinopathy, fundus hemorrhage, vitreous opacity, glaucoma or optic nerve pathological changes and the like, and 50 patients who suffer from the blurred vision are selected in the outpatient service of a hospital randomly to take the medicament. In the administration method and dosage, adults take twice every day, and takes 5 grams every time; for the children, the dosage is reduced by half; and 20 days is one treatment course, the total cure rate is 69 percent, the total cure rate of two treatment courses is 86.3, and the cure rate of three treatment course is 97.2 percent.

Antagonists of cation-independent mannose 6-phosphate/insulin-like growth factor-II receptor are provided for attenuation of CTGF signaling in a method of down-regulation of receptor signaling and downstream decreased signaling of connective tissue growth factor in ocular disorders involving inappropriate CTGF signaling. Ocular disorders involving inappropriate CTGF signaling include ocular hypertension, glaucoma, glaucomatous retinopathy, optic neuropathy, macular degeneration, diabetic retinopathy, choroidal neovascularization, and proliferative vitreoretinopathy, for example. Such disorders are treated by administering antagonists of the present invention.

An isolated polynucleotide encoding human glutamate cysteine ligase and human glutathione synthase, as well as expression constructs, vectors and pharmaceutical compositions comprising the same, are provided herein. Methods for use of these compositions in the treatment oxidative stress related diseases, including, for example, atherosclerosis, Parkinson's disease, heart failure, myocardial infarction, Alzheimer's disease, diabetes, chronic lung disease, diseases associated with mitochondrial dysfunction, diseases associated with chronic inflammation, retinitis pigmentosa, wet age related macular degeneration, dry age related macular degeneration, diabetic retinopathy, Lebers optic neuropathy, and optic neuritis are also provided.

An apparatus and a method for diagnosing optic neuropathic diseases including glaucoma, are provided. The apparatus for diagnosing optical neuropathic diseases measures a thickness of a retinal nerve fiber layer (RNFL) using methods such as optical coherence tomography (OCT) and scanning laser polarimetry, and includes a scanning unit which scans along an optic nerve margin in the proximity of an optic nerve head, a pattern analyzing unit which analyzes a pattern of the RNFL scanned by the scanning unit, and a disease determining unit which determines a presence of the disease based on the pattern of the RNFL analyzed by the pattern analyzing unit.